BACKGROUND: Many epidemiological studies have shown that the genetic factors of the host play a role in the variability of clinical response to infection caused by M. leprae. With the purpose of identifying genes of susceptibility, the present study investigated the possible role of HLA-DRB1 and DQA1/DQB1 alleles in susceptibility to leprosy, and whether they account for the heterogeneity in immune responses observed following infection in a Southern Brazilian population. METHODS: One hundred and sixty-nine leprosy patients and 217 healthy controls were analyzed by polymerase chain reaction amplification and reverse hybridization with sequence-specific oligonucleotide probes and sequence-specific primers (One Lambda, CA, USA). RESULTS: There was a positive association of HLA-DRB1*16 (*1601 and *1602) with leprosy per se (7.3% vs. 3.2%, P = 0.01, OR = 2.52, CI = 1.26-5.01), in accord with previous serological studies, which showed DR2 as a marker of leprosy. Although, HLA-DQA1*05 frequency (29.8% vs. 20.9%, P = 0.0424, OR = 1.61, CI = 1.09-2.39) was higher in patients, and HLA-DQA1*02 (3.0% vs. 7.5%, P = 0.0392, OR = 0.39, CI = 0.16 - 0.95) and HLA-DQA1*04 (4.0% vs. 9.1%, P = 0.0314, OR = 0.42, CI = 0.19 - 0.93) frequencies lower, P-values were not significant after the Bonferroni's correction. Furthermore, HLA-DRB1*1601 (9.0% vs. 1.8%; P = 0.0016; OR = 5.81; CI = 2.05-16.46) was associated with susceptibility to borderline leprosy compared to control group, and while HLA-DRB1*08 (11.2% vs. 1.2%; P = 0.0037; OR = 12.00; CI = 1.51 - 95.12) was associated with susceptibility to lepromatous leprosy, when compared to tuberculoid leprosy, DRB1*04 was associated to protection. CONCLUSION: These data confirm the positive association of HLA-DR2 (DRB1*16) with leprosy per se, and the protector effect of DRB1*04 against lepromatous leprosy in Brazilian patients.
BACKGROUND: Many epidemiological studies have shown that the genetic factors of the host play a role in the variability of clinical response to infection caused by M. leprae. With the purpose of identifying genes of susceptibility, the present study investigated the possible role of HLA-DRB1 and DQA1/DQB1 alleles in susceptibility to leprosy, and whether they account for the heterogeneity in immune responses observed following infection in a Southern Brazilian population. METHODS: One hundred and sixty-nine leprosypatients and 217 healthy controls were analyzed by polymerase chain reaction amplification and reverse hybridization with sequence-specific oligonucleotide probes and sequence-specific primers (One Lambda, CA, USA). RESULTS: There was a positive association of HLA-DRB1*16 (*1601 and *1602) with leprosy per se (7.3% vs. 3.2%, P = 0.01, OR = 2.52, CI = 1.26-5.01), in accord with previous serological studies, which showed DR2 as a marker of leprosy. Although, HLA-DQA1*05 frequency (29.8% vs. 20.9%, P = 0.0424, OR = 1.61, CI = 1.09-2.39) was higher in patients, and HLA-DQA1*02 (3.0% vs. 7.5%, P = 0.0392, OR = 0.39, CI = 0.16 - 0.95) and HLA-DQA1*04 (4.0% vs. 9.1%, P = 0.0314, OR = 0.42, CI = 0.19 - 0.93) frequencies lower, P-values were not significant after the Bonferroni's correction. Furthermore, HLA-DRB1*1601 (9.0% vs. 1.8%; P = 0.0016; OR = 5.81; CI = 2.05-16.46) was associated with susceptibility to borderline leprosy compared to control group, and while HLA-DRB1*08 (11.2% vs. 1.2%; P = 0.0037; OR = 12.00; CI = 1.51 - 95.12) was associated with susceptibility to lepromatous leprosy, when compared to tuberculoid leprosy, DRB1*04 was associated to protection. CONCLUSION: These data confirm the positive association of HLA-DR2 (DRB1*16) with leprosy per se, and the protector effect of DRB1*04 against lepromatous leprosy in Brazilian patients.
Authors: C M Probst; E P Bompeixe; N F Pereira; M M de O Dalalio; J E Visentainer; L T Tsuneto; M L Petzl-Erler Journal: Hum Biol Date: 2000-08 Impact factor: 0.553
Authors: E N Miller; S E Jamieson; C Joberty; M Fakiola; D Hudson; C S Peacock; H J Cordell; M-A Shaw; Z Lins-Lainson; J J Shaw; F Ramos; F Silveira; J M Blackwell Journal: Genes Immun Date: 2004-01 Impact factor: 2.676
Authors: P R Vanderborght; A G Pacheco; M E Moraes; G Antoni; M Romero; A Verville; V H Thai; N T Huong; N N Ba; E Schurr; E N Sarno; M O Moraes Journal: Genes Immun Date: 2007-03-29 Impact factor: 2.676
Authors: Kathryn M Dupnik; Thomas B Bair; Andressa O Maia; Francianne M Amorim; Marcos R Costa; Tatjana S L Keesen; Joanna G Valverde; Maria do Carmo A P Queiroz; Lúcio L Medeiros; Nelly L de Lucena; Mary E Wilson; Mauricio L Nobre; Warren D Johnson; Selma M B Jeronimo Journal: J Infect Dis Date: 2014-11-14 Impact factor: 5.226
Authors: L H Sampaio; A L M Sousa; M C Barcelos; S G Reed; M M A Stefani; M S Duthie Journal: Eur J Clin Microbiol Infect Dis Date: 2011-11-12 Impact factor: 3.267
Authors: Thomas P Hofer; Marion Frankenberger; Irene Heimbeck; Dorothe Burggraf; Matthias Wjst; Adam K A Wright; Maria Kerscher; Susanne Nährig; Rudolf M Huber; Rainald Fischer; Loems Ziegler-Heitbrock Journal: J Mol Med (Berl) Date: 2014-08-23 Impact factor: 4.599
Authors: Priscila Verchai Uaska Sartori; Gerson O Penna; Samira Bührer-Sékula; Maria A A Pontes; Heitor S Gonçalves; Rossilene Cruz; Marcos C L Virmond; Ida M F Dias-Baptista; Patricia S Rosa; Maria L F Penna; Vinicius Medeiros Fava; Mariane M A Stefani; Marcelo Távora Mira Journal: Sci Rep Date: 2020-01-28 Impact factor: 4.379